Common Stock, Par Value $0.001 Per Share
- Symbol
- LUCD
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 3.01, 9.01 · 8-K
Lucid Diagnostics Inc.
LUCDNASDAQEQUITYCurrent
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item Notice 3.01. of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. On October 12, 2026, Lucid Diagnostics Inc. (the “ Company ”) received a notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through October 9, 2026), the closing bid price of the Company’…
Company context
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard ® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck ® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
Current securities
Recent company filings
- Unregistered Sales of Equity Securities · Material Modification to Rights of Security Holders · Amendments to Articles of Incorporation or Bylaws; Change in Fiscal YearOct 22, 2026
- Regulation FD DisclosureSep 22, 2026
- Results of Operations and Financial Condition · Regulation FD DisclosureAug 13, 2026
- 10-Q filingAug 12, 2026
- Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year · Submission of Matters to a Vote of Security HoldersJun 24, 2026
Registered securities in this filing
LUCID DIAGNOSTICS INC. · 8-K · Filed 2026-10-16
Disclosure sections
Item 3.01Item 3.01 - Notice of Delisting
Item Notice
3.01. of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.
On
October 12, 2026, Lucid Diagnostics Inc. (the “ Company ”) received a notice from the Listing Qualifications Department
of The Nasdaq Stock Market LLC (“ Nasdaq ”) stating that, for the prior 30 consecutive business days (through October
9, 2026), the closing bid price of the Company’s common stock had been below the minimum of $1 per share required for continued
listing on the Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2).
The
notification letter stated that the Company would be afforded 180 calendar days (until April 12, 2027) to regain compliance. In order
to regain compliance, the closing bid price of the Company’s common stock must be at least $1 for a minimum of ten consecutive
business days. The notification letter also stated that, in the event the Company does not regain compliance within the initial 180-day
period, the Company may be eligible for an additional 180-day period. If the Company is not eligible for the additional 180-day period,
or if it appears to the Nasdaq staff that the Company will not be able to cure the deficiency, the Nasdaq Listing Qualifications Department
will provide notice after the end of the initial 180-day period that the Company’s securities will be subject to delisting.
The
Nasdaq notification has no effect at this time on the listing of the Company’s common stock, and the common stock will continue
to trade uninterrupted under the symbol “LUCD.” The Company intends to consider all available options to regain compliance
with the Nasdaq listing standards.